Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis

Józefa Wesierska-Gadek, Edward Penner, Pier Maria Battezzati, Carlo Selmi, Massimo Zuin, Eva Hitchman, Howard J. Worman, M. Eric Gershwin, Mauro Podda, Pietro Invernizzi

Research output: Contribution to journalArticle

139 Citations (Scopus)

Abstract

Although there have been significant advances in understanding the clinical and biochemical features of primary biliary cirrhosis (PBC), there is still a paucity of data on the usefulness of biomarkers as prognostic indicators. This is particularly important at the time of initial diagnosis. Indeed, the widespread use of antimitochondrial antibody testing has led to an earlier diagnosis of asymptomatic PBC and it is difficult to predict which patients will experience a benign versus a rapidly progressive course. To address this issue, we examined a unique population of 127 newly diagnosed patients with PBC during a 15-year period of observation that began in January 1990. Sera from these patients were analyzed for antimitochondrial, antinuclear, and anti-smooth muscle antibodies, and immunoblotting was performed for nuclear pore complex (NPC). The patients were then followed up longitudinally using biochemical liver function tests. No patient was under any medical therapy for PBC at the time of the initial sera collection. Data were analyzed based not only on the clinical features, but also the Mayo score and specific outcome measures, including time to death, need for liver transplantation, and complication free survival. Among patients with early disease, bilirubin increased to >2 mg/dL in the anti-NPC(+) patients (26% vs. 5%, P = .019). Anti-NPC antibodies remained stable or slightly increased over the period of observation. In conclusion, anti-NPC identifies patients likely to experience an unfavorable clinical course and more rapid disease progression.

Original languageEnglish (US)
Pages (from-to)1135-1144
Number of pages10
JournalHepatology
Volume43
Issue number5
DOIs
StatePublished - May 2006

Fingerprint

Biliary Liver Cirrhosis
Autoantibodies
Nuclear Pore
Antibodies
Observation
Liver Function Tests
Serum
Bilirubin
Immunoblotting
Liver Transplantation
Smooth Muscle
Disease Progression
Early Diagnosis
Biomarkers
Outcome Assessment (Health Care)
Survival

ASJC Scopus subject areas

  • Hepatology

Cite this

Wesierska-Gadek, J., Penner, E., Battezzati, P. M., Selmi, C., Zuin, M., Hitchman, E., ... Invernizzi, P. (2006). Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis. Hepatology, 43(5), 1135-1144. https://doi.org/10.1002/hep.21172

Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis. / Wesierska-Gadek, Józefa; Penner, Edward; Battezzati, Pier Maria; Selmi, Carlo; Zuin, Massimo; Hitchman, Eva; Worman, Howard J.; Gershwin, M. Eric; Podda, Mauro; Invernizzi, Pietro.

In: Hepatology, Vol. 43, No. 5, 05.2006, p. 1135-1144.

Research output: Contribution to journalArticle

Wesierska-Gadek, J, Penner, E, Battezzati, PM, Selmi, C, Zuin, M, Hitchman, E, Worman, HJ, Gershwin, ME, Podda, M & Invernizzi, P 2006, 'Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis', Hepatology, vol. 43, no. 5, pp. 1135-1144. https://doi.org/10.1002/hep.21172
Wesierska-Gadek J, Penner E, Battezzati PM, Selmi C, Zuin M, Hitchman E et al. Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis. Hepatology. 2006 May;43(5):1135-1144. https://doi.org/10.1002/hep.21172
Wesierska-Gadek, Józefa ; Penner, Edward ; Battezzati, Pier Maria ; Selmi, Carlo ; Zuin, Massimo ; Hitchman, Eva ; Worman, Howard J. ; Gershwin, M. Eric ; Podda, Mauro ; Invernizzi, Pietro. / Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis. In: Hepatology. 2006 ; Vol. 43, No. 5. pp. 1135-1144.
@article{f68d620524054a8498fdbf7f34a38e7f,
title = "Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis",
abstract = "Although there have been significant advances in understanding the clinical and biochemical features of primary biliary cirrhosis (PBC), there is still a paucity of data on the usefulness of biomarkers as prognostic indicators. This is particularly important at the time of initial diagnosis. Indeed, the widespread use of antimitochondrial antibody testing has led to an earlier diagnosis of asymptomatic PBC and it is difficult to predict which patients will experience a benign versus a rapidly progressive course. To address this issue, we examined a unique population of 127 newly diagnosed patients with PBC during a 15-year period of observation that began in January 1990. Sera from these patients were analyzed for antimitochondrial, antinuclear, and anti-smooth muscle antibodies, and immunoblotting was performed for nuclear pore complex (NPC). The patients were then followed up longitudinally using biochemical liver function tests. No patient was under any medical therapy for PBC at the time of the initial sera collection. Data were analyzed based not only on the clinical features, but also the Mayo score and specific outcome measures, including time to death, need for liver transplantation, and complication free survival. Among patients with early disease, bilirubin increased to >2 mg/dL in the anti-NPC(+) patients (26{\%} vs. 5{\%}, P = .019). Anti-NPC antibodies remained stable or slightly increased over the period of observation. In conclusion, anti-NPC identifies patients likely to experience an unfavorable clinical course and more rapid disease progression.",
author = "J{\'o}zefa Wesierska-Gadek and Edward Penner and Battezzati, {Pier Maria} and Carlo Selmi and Massimo Zuin and Eva Hitchman and Worman, {Howard J.} and Gershwin, {M. Eric} and Mauro Podda and Pietro Invernizzi",
year = "2006",
month = "5",
doi = "10.1002/hep.21172",
language = "English (US)",
volume = "43",
pages = "1135--1144",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "5",

}

TY - JOUR

T1 - Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis

AU - Wesierska-Gadek, Józefa

AU - Penner, Edward

AU - Battezzati, Pier Maria

AU - Selmi, Carlo

AU - Zuin, Massimo

AU - Hitchman, Eva

AU - Worman, Howard J.

AU - Gershwin, M. Eric

AU - Podda, Mauro

AU - Invernizzi, Pietro

PY - 2006/5

Y1 - 2006/5

N2 - Although there have been significant advances in understanding the clinical and biochemical features of primary biliary cirrhosis (PBC), there is still a paucity of data on the usefulness of biomarkers as prognostic indicators. This is particularly important at the time of initial diagnosis. Indeed, the widespread use of antimitochondrial antibody testing has led to an earlier diagnosis of asymptomatic PBC and it is difficult to predict which patients will experience a benign versus a rapidly progressive course. To address this issue, we examined a unique population of 127 newly diagnosed patients with PBC during a 15-year period of observation that began in January 1990. Sera from these patients were analyzed for antimitochondrial, antinuclear, and anti-smooth muscle antibodies, and immunoblotting was performed for nuclear pore complex (NPC). The patients were then followed up longitudinally using biochemical liver function tests. No patient was under any medical therapy for PBC at the time of the initial sera collection. Data were analyzed based not only on the clinical features, but also the Mayo score and specific outcome measures, including time to death, need for liver transplantation, and complication free survival. Among patients with early disease, bilirubin increased to >2 mg/dL in the anti-NPC(+) patients (26% vs. 5%, P = .019). Anti-NPC antibodies remained stable or slightly increased over the period of observation. In conclusion, anti-NPC identifies patients likely to experience an unfavorable clinical course and more rapid disease progression.

AB - Although there have been significant advances in understanding the clinical and biochemical features of primary biliary cirrhosis (PBC), there is still a paucity of data on the usefulness of biomarkers as prognostic indicators. This is particularly important at the time of initial diagnosis. Indeed, the widespread use of antimitochondrial antibody testing has led to an earlier diagnosis of asymptomatic PBC and it is difficult to predict which patients will experience a benign versus a rapidly progressive course. To address this issue, we examined a unique population of 127 newly diagnosed patients with PBC during a 15-year period of observation that began in January 1990. Sera from these patients were analyzed for antimitochondrial, antinuclear, and anti-smooth muscle antibodies, and immunoblotting was performed for nuclear pore complex (NPC). The patients were then followed up longitudinally using biochemical liver function tests. No patient was under any medical therapy for PBC at the time of the initial sera collection. Data were analyzed based not only on the clinical features, but also the Mayo score and specific outcome measures, including time to death, need for liver transplantation, and complication free survival. Among patients with early disease, bilirubin increased to >2 mg/dL in the anti-NPC(+) patients (26% vs. 5%, P = .019). Anti-NPC antibodies remained stable or slightly increased over the period of observation. In conclusion, anti-NPC identifies patients likely to experience an unfavorable clinical course and more rapid disease progression.

UR - http://www.scopus.com/inward/record.url?scp=33646571925&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646571925&partnerID=8YFLogxK

U2 - 10.1002/hep.21172

DO - 10.1002/hep.21172

M3 - Article

C2 - 16628641

AN - SCOPUS:33646571925

VL - 43

SP - 1135

EP - 1144

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 5

ER -